Medical News Today -
28 Oct 2013 11:00
Verona Pharma plc (AIM: VRP), the drug development company focused on "first-in-class" medicines to treat respiratory diseases, announces that a new research paper entitled "Efficacy and safety of RPL554, a dual PDE3 and PDE4 inhibitor, in healthy volunteers and in patients with asthma or chronic obstructive pulmonary disease: findings from four clinical trials" is now available on-line in The Lancet Respiratory Medicine...
Share this Article